Abstract:Cullin-RING E3 ligases (CRLs) are the major components of ubiquitin-proteasome system, responsible for ubiquitylation and subsequent degradation of thousands of cellular proteins. CRLs play vital roles in the regulation of multiple cellular processes, including cell cycle, cell apoptosis, DNA replication, signalling transduction among the others, and are frequently dysregulated in many human cancers. The discovery of specific neddylation inhibitors, represented by MLN4924, has validated CRLs as promising targets for anti-cancer therapies with a growing market. Recent studies have focused on the discovery of the CRLs inhibitors by a variety of approaches, including high through-put screen, virtual screen or structure-based drug design. The field is, however, still facing the major challenging, since CRLs are a large multi-unit protein family without typical active pockets to facilitate the drug design, and enzymatic activity is mainly dependent on undruggable protein-protein interactions and dynamic conformation changes. Up to now, most reported CRLs inhibitors are aiming at targeting the F-box family proteins (e.g., SKP2, β-TrCP and FBXW7), the substrate recognition subunit of SCF E3 ligases. Other studies reported few small molecule inhibitors targeting the UBE2M-DCN1 interaction, which specifically inhibits CRL3/CRL1 by blocking the cullin neddylation. On the other hand, several CRL activators have been reported, such as plant auxin and immunomodulatory imide drugs, thalidomide. Finally, proteolysis-targeting chimeras (PROTACs) has emerged as a new technology in the field of drug discovery, specifically targeting the undruggable protein-protein interaction. The technique connects the small molecule that selectively binds to a target protein to a CRL E3 via a chemical linker to trigger the degradation of target protein. The PROTAC has become a hotspot in the field of E3-ligase-based anti-cancer drug discovery.

Targeting Cul3-scaffold E3 ligase complex <i>via</i> KLHL substrate adaptors for cancer therapy

The Functions and Properties of Cullin-5, a Potential Therapeutic Target for Cancers.

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery

Functional analysis of Cullin 3 E3 ligases in tumorigenesis

Targeting SCF E3 Ligases for Cancer Therapies

The emerging role for Cullin 4 family of E3 ligases in tumorigenesis

Targeting kelch-like (KLHL) proteins: Achievements, challenges and perspectives

CRL2KLHDC3 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression

The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer

CRL3s: The BTB-CUL3-RING E3 Ubiquitin Ligases

Cullin-RING Ligases as attractive anti-cancer targets.

Cullin3–KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression

A patent review of SCF E3 ligases inhibitors for cancer：Structural design, pharmacological activities and structure-activity relationship

The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies

CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma

Cullin-Ring Ligase 5: Functional Characterization And Its Role In Human Cancers

Targeting cullin neddylation for cancer and fibrotic diseases

Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy

Cullin-RING Ligase 5: Functional Characterization and Its Role in Human Cancers.

Dynamic molecular architecture and substrate recruitment of cullin3–RING E3 ligase CRL3 KBTBD2